Art. -Nr.: HY-N1451

Betulonic acid

Name: Betulonic acid
Brand: MedChemExpress
SKU: HY-N1451
Price: 32.00 USD
Availability: InStock
Rating: 5 (5 reviews)

(Synonyms: Betunolic acid; Liquidambaric acid; (+)-Betulonic acid)

5 Cited Publications

Kundenbewertung

Based on 5 publication(s) in Google Scholar

Betulonic acid (Betunolic acid), a naturally occurring triterpene, is found in many plants. Betulonic acid has anti-tumor, anti-inflammatory, antiparasitic and anti-viral (HSV-1) activities.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.52%
CAS. Nr.: 4481-62-3
Formel: C₃₀H₄₆O₃
Molecular Weight:454.68

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Betulonic acid Chemical Structure

CAS. Nr.: 4481-62-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (5)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll (1)
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Betulonic acid (Betunolic acid), a naturally occurring triterpene, is found in many plants. Betulonic acid has anti-tumor, anti-inflammatory, antiparasitic and anti-viral (HSV-1) activities^[2]^[1]^[3]^[4].

IC₅₀ & Target

Plasmodium

HSV-1

Alle Parasite Isoform-spezifische Produkte anzeigen :

Alle HSV Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
518A2	EC₅₀	29 μM Compound: 4	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 26547057]
518A2	IC₅₀	10.42 μM Compound: 2	Cytotoxicity against human 518A2 cells after 96 hrs by SRB colorimetric assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB colorimetric assay	[PMID: 20472329]
518A2	IC₅₀	12.93 μM Compound: 2	Cytotoxicity against human 518A2 cells assessed as cell viability after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells assessed as cell viability after 96 hrs by SRB assay	[PMID: 23973824]
8505C	IC₅₀	14 μM Compound: 2	Cytotoxicity against human 8505C cells assessed as cell viability after 96 hrs by SRB assay Cytotoxicity against human 8505C cells assessed as cell viability after 96 hrs by SRB assay	[PMID: 23973824]
A253 cell line	IC₅₀	10.05 μM Compound: 2	Cytotoxicity against human A253 cells after 96 hrs by SRB colorimetric assay Cytotoxicity against human A253 cells after 96 hrs by SRB colorimetric assay	[PMID: 20472329]
A2780	EC₅₀	20.4 μM Compound: 4	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 26547057]
A2780	EC₅₀	4.7 μM Compound: 2	Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32956968]
A2780	IC₅₀	2.98 μM Compound: 2	Cytotoxicity against human A2780 cells after 96 hrs by SRB colorimetric assay Cytotoxicity against human A2780 cells after 96 hrs by SRB colorimetric assay	[PMID: 20472329]
A2780	IC₅₀	5.97 μM Compound: 2	Cytotoxicity against human A2780 cells assessed as cell viability after 96 hrs by SRB assay Cytotoxicity against human A2780 cells assessed as cell viability after 96 hrs by SRB assay	[PMID: 23973824]
A-375	EC₅₀	14.3 μM Compound: 2	Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32956968]
A-375	IC₅₀	28.9 μM Compound: 1, BetA, Betulonic acid	Cytotoxicity against human A375 cells after 72 hrs by MTT assay Cytotoxicity against human A375 cells after 72 hrs by MTT assay	[PMID: 25874331]
A-431	IC₅₀	3.26 μM Compound: 2	Cytotoxicity against human A431 cells after 96 hrs by SRB colorimetric assay Cytotoxicity against human A431 cells after 96 hrs by SRB colorimetric assay	[PMID: 20472329]
A549	EC₅₀	25.9 μM Compound: 4	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 26547057]
A549	ED₅₀	>10 μg/mL Compound: 13	Cytotoxic activity against human A549 cell line was measured after 72 hr using MTT assay Cytotoxic activity against human A549 cell line was measured after 72 hr using MTT assay	[PMID: 15225732]
A549	IC₅₀	10.09 μM Compound: 2	Cytotoxicity against human A549 cells after 96 hrs by SRB colorimetric assay Cytotoxicity against human A549 cells after 96 hrs by SRB colorimetric assay	[PMID: 20472329]
A549	IC₅₀	10.42 μM Compound: 2	Cytotoxicity against human A549 cells assessed as cell viability after 96 hrs by SRB assay Cytotoxicity against human A549 cells assessed as cell viability after 96 hrs by SRB assay	[PMID: 23973824]
A549	IC₅₀	15 μM Compound: 1b	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 17371067]
A549	IC₅₀	15 μM Compound: 7, betulonic acid	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 15270560]
A549	IC₅₀	40 μM Compound: 5a	Cytotoxicity against human A549 cells incubated for 72 hrs by MTS assay Cytotoxicity against human A549 cells incubated for 72 hrs by MTS assay	[PMID: 31677446]
A549	IC₅₀	40 μM Compound: 1a	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 36174412]
A549	IC₅₀	5.7 μM Compound: 7	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by SRB assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 28500966]
A549	IC₅₀	8.93 μg/mL Compound: Betunolic acid	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 21106454]
Bcap37	IC₅₀	25.7 μM Compound: 1, BetA, Betulonic acid	Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay	[PMID: 25874331]
BJ	IC₅₀	39 μM Compound: 1a	Cytotoxicity against human BJ cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human BJ cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 36174412]
BJ	IC₅₀	39.5 μM Compound: 5a	Cytotoxicity against human BJ cells incubated for 72 hrs by MTS assay Cytotoxicity against human BJ cells incubated for 72 hrs by MTS assay	[PMID: 31677446]
BRISTOL8	ED₅₀	2.6 μg/mL Compound: 13	Cytotoxic activity against human BRISTOL8 cell line was measured after 72 hr using MTT assay Cytotoxic activity against human BRISTOL8 cell line was measured after 72 hr using MTT assay	[PMID: 15225732]
BV-2	IC₅₀	>100 μM Compound: 28	Anti-neuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Anti-neuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 25466192]
BV-2	IC₅₀	60.7 μM Compound: 1	Anti-neuroinflammatory activity in mouse BV-2 cells assessed as inhibition of LPS-induced NO production incubated for 48 hrs by Griess reagent based assay Anti-neuroinflammatory activity in mouse BV-2 cells assessed as inhibition of LPS-induced NO production incubated for 48 hrs by Griess reagent based assay	[PMID: 34546050]
Ca9-22	IC₅₀	14.47 μg/mL Compound: Betunolic acid	Cytotoxicity against human Ca9-22 cells by MTT assay Cytotoxicity against human Ca9-22 cells by MTT assay	[PMID: 21106454]
CCRF-CEM	ED₅₀	4.4 μg/mL Compound: 13	Cytotoxic activity against human CEM.CM3 cell line was measured after 72 hr using MTT assay Cytotoxic activity against human CEM.CM3 cell line was measured after 72 hr using MTT assay	[PMID: 15225732]
CCRF-CEM	IC₅₀	14 μM Compound: 2a	Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTS assay Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTS assay	[PMID: 27236068]
CCRF-CEM	IC₅₀	17 μM Compound: 7, betulonic acid	Cytotoxicity against human CEM cells after 72 hrs by MTT assay Cytotoxicity against human CEM cells after 72 hrs by MTT assay	[PMID: 15270560]
CCRF-CEM	IC₅₀	20 μM Compound: 1b	Cytotoxicity against human CEM cells after 72 hrs by MTT assay Cytotoxicity against human CEM cells after 72 hrs by MTT assay	[PMID: 17371067]
CCRF-CEM	IC₅₀	20 μM Compound: 3	Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay	[PMID: 22551630]
CCRF-CEM	IC₅₀	8.4 μM Compound: 5a	Cytotoxicity against human CCRF-CEM cells incubated for 72 hrs by MTS assay Cytotoxicity against human CCRF-CEM cells incubated for 72 hrs by MTS assay	[PMID: 31677446]
CCRF-CEM	IC₅₀	8.4 μM Compound: 1a	Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 36174412]
CEM-DNR	IC₅₀	11 μM Compound: 1a	Cytotoxicity against human CEM-DNR cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human CEM-DNR cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 36174412]
CHO	EC₅₀	4.71 μM Compound: 7	Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay	[PMID: 19911773]
COLO 205	IC₅₀	36.8 μM Compound: 17	Cytotoxicity against human COLON205 cells after 48 hrs by MTT assay Cytotoxicity against human COLON205 cells after 48 hrs by MTT assay	[PMID: 17346076]
COS-1	EC₅₀	0 μM Compound: 7	Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay	[PMID: 19911773]
DU-145	CC₅₀	139 μM Compound: 9	Cytotoxic activity in human DU145 cells by sulforhodamine B assay Cytotoxic activity in human DU145 cells by sulforhodamine B assay	[PMID: 29120172]
DU-145	ED₅₀	3.1 μg/mL Compound: 13	Cytotoxic activity against human DU145 cell line was measured after 72 hr using MTT assay Cytotoxic activity against human DU145 cell line was measured after 72 hr using MTT assay	[PMID: 15225732]
DU-145	IC₅₀	>500 μM Compound: 9	Antiproliferative activity in human DU145 cells by sulforhodamine B assay Antiproliferative activity in human DU145 cells by sulforhodamine B assay	[PMID: 29120172]
DU-145	IC₅₀	36 μM Compound: 7, betulonic acid	Cytotoxicity against human DU145 cells after 72 hrs by MTT assay Cytotoxicity against human DU145 cells after 72 hrs by MTT assay	[PMID: 15270560]
ECV-304	IC₅₀	<4 μg/mL Compound: 12	Cytotoxic activity against ECV304 (human endothelial) cell line. Cytotoxic activity against ECV304 (human endothelial) cell line.	[PMID: 15149668]
ECV-304	IC₅₀	0.28 μg/mL Compound: 2	Half-maximal cytotoxic concentration of compound against endothelial cell line ECV304 Half-maximal cytotoxic concentration of compound against endothelial cell line ECV304	[PMID: 15081004]
FaDu	EC₅₀	17.4 μM Compound: 2	Cytotoxicity against human FaDu cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human FaDu cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32956968]
Fibroblast	CC₅₀	>100 μM Compound: 2	Cytotoxicity against mock-infected human embryonic lung fibroblast cells incubated for 5 days by MTS assay Cytotoxicity against mock-infected human embryonic lung fibroblast cells incubated for 5 days by MTS assay	[PMID: 33877845]
H9	EC₅₀	0.22 μg/mL Compound: 4	Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral p24 antigen levels after 4 days by ELISA Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral p24 antigen levels after 4 days by ELISA	[PMID: 11678650]
H9	IC₅₀	1.8 μg/mL Compound: 4	Cytotoxicity against human H9 cells Cytotoxicity against human H9 cells	[PMID: 11678650]
HCT-116	IC₅₀	>10 μM Compound: 7	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by SRB assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 28500966]
HCT-116	IC₅₀	2.61 μM Compound: 6	Antiproliferative activity against human HCT116 cells after 3 days by XTT assay Antiproliferative activity against human HCT116 cells after 3 days by XTT assay	[PMID: 19691293]
HCT-116	IC₅₀	38 μM Compound: 1a	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 36174412]
HCT-116	IC₅₀	38.1 μM Compound: 5a	Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTS assay Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTS assay	[PMID: 31677446]
HCT-116	IC₅₀	49.4 μM Compound: 5a	Cytotoxicity against p53 knockout human HCT116 cells incubated for 72 hrs by MTS assay Cytotoxicity against p53 knockout human HCT116 cells incubated for 72 hrs by MTS assay	[PMID: 31677446]
HEK293	CC₅₀	>500 μM Compound: 9	Cytotoxic activity in HEK293 cells by sulforhodamine B assay Cytotoxic activity in HEK293 cells by sulforhodamine B assay	[PMID: 29120172]
HEK293	IC₅₀	>500 μM Compound: 9	Antiproliferative activity in HEK293 cells by sulforhodamine B assay Antiproliferative activity in HEK293 cells by sulforhodamine B assay	[PMID: 29120172]
HeLa	CC₅₀	>500 μM Compound: 9	Cytotoxic activity in human HeLa cells by sulforhodamine B assay Cytotoxic activity in human HeLa cells by sulforhodamine B assay	[PMID: 29120172]
HeLa	IC₅₀	>500 μM Compound: 9	Antiproliferative activity in human HeLa cells by sulforhodamine B assay Antiproliferative activity in human HeLa cells by sulforhodamine B assay	[PMID: 29120172]
Hep 3B2	IC₅₀	13.81 μg/mL Compound: Betunolic acid	Cytotoxicity against human Hep3B cells by MTT assay Cytotoxicity against human Hep3B cells by MTT assay	[PMID: 21106454]
HEp-2	CC₅₀	>500 μM Compound: 9	Cytotoxic activity in human Hep2 cells by sulforhodamine B assay Cytotoxic activity in human Hep2 cells by sulforhodamine B assay	[PMID: 29120172]
HEp-2	IC₅₀	>500 μM Compound: 9	Antiproliferative activity in human Hep2 cells by sulforhodamine B assay Antiproliferative activity in human Hep2 cells by sulforhodamine B assay	[PMID: 29120172]
HepG2	CC₅₀	150.5 μM Compound: 4b	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 29326018]
HepG2	IC₅₀	4.32 μg/mL Compound: Betunolic acid	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 21106454]
HT-29	EC₅₀	18.5 μM Compound: 2	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32956968]
HT-29	IC₅₀	10.02 μM Compound: 2	Cytotoxicity against human HT-29 cells after 96 hrs by SRB colorimetric assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB colorimetric assay	[PMID: 20472329]
HT-29	IC₅₀	17 μM Compound: 1b	Cytotoxicity against human HT29 cells after 72 hrs by MTT assay Cytotoxicity against human HT29 cells after 72 hrs by MTT assay	[PMID: 17371067]
HT-29	IC₅₀	17 μM Compound: 7, betulonic acid	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 15270560]
Jurkat	ED₅₀	0.4 μg/mL Compound: 13	Cytotoxic activity against human JurkatE6.1 cell line was measured after 72 h using MTT assay Cytotoxic activity against human JurkatE6.1 cell line was measured after 72 h using MTT assay	[PMID: 15225732]
K562	IC₅₀	13.6 μM Compound: 5a	Cytotoxicity against human K562 cells incubated for 72 hrs by MTS assay Cytotoxicity against human K562 cells incubated for 72 hrs by MTS assay	[PMID: 31677446]
K562	IC₅₀	14 μM Compound: 1a	Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 36174412]
K562	IC₅₀	16.1 μM Compound: 17	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 17346076]
K562	IC₅₀	17 μM Compound: 7, betulonic acid	Cytotoxicity against paclitaxel-resistant human K562 cells after 72 hrs by MTT assay Cytotoxicity against paclitaxel-resistant human K562 cells after 72 hrs by MTT assay	[PMID: 15270560]
K562	IC₅₀	6 μM Compound: 1b	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 17371067]
K562	IC₅₀	6 μM Compound: 7, betulonic acid	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 15270560]
K562/Adr	IC₅₀	48.4 μM Compound: 17	Cytotoxicity against human doxorubicin-resistant K562/Adr cells in presence of 1 uM doxorubicin after 48 hrs by MTT assay Cytotoxicity against human doxorubicin-resistant K562/Adr cells in presence of 1 uM doxorubicin after 48 hrs by MTT assay	[PMID: 17346076]
K562/Adr	IC₅₀	73.5 μM Compound: 17	Cytotoxicity against human doxorubicin-resistant K562/Adr cells after 48 hrs by MTT assay Cytotoxicity against human doxorubicin-resistant K562/Adr cells after 48 hrs by MTT assay	[PMID: 17346076]
KB	CC₅₀	>500 μM Compound: 9	Cytotoxic activity in human KB cells by sulforhodamine B assay Cytotoxic activity in human KB cells by sulforhodamine B assay	[PMID: 29120172]
KB	ED₅₀	2.5 μg/mL Compound: 3	Cytotoxicity against human epidermoid carcinoma of the mouth (KB) cell line. Cytotoxicity against human epidermoid carcinoma of the mouth (KB) cell line.	[PMID: 9873420]
KB	IC₅₀	>500 μM Compound: 9	Antiproliferative activity in human KB cells by sulforhodamine B assay Antiproliferative activity in human KB cells by sulforhodamine B assay	[PMID: 29120172]
KB	IC₅₀	3.8 μM Compound: 17	Cytotoxicity against human KB cells after 48 hrs by MTT assay Cytotoxicity against human KB cells after 48 hrs by MTT assay	[PMID: 17346076]
L132	ED₅₀	>10 μg/mL Compound: 13	Cytotoxic activity against human L132 cell line was measured after 72 hr using MTT assay Cytotoxic activity against human L132 cell line was measured after 72 hr using MTT assay	[PMID: 15225732]
MCF7	CC₅₀	>500 μM Compound: 9	Cytotoxic activity in human MCF7 cells by sulforhodamine B assay Cytotoxic activity in human MCF7 cells by sulforhodamine B assay	[PMID: 29120172]
MCF7	EC₅₀	12 μM Compound: 2	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32956968]
MCF7	EC₅₀	25.9 μM Compound: 4	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 26547057]
MCF7	IC₅₀	>10 μM Compound: 7	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 28500966]
MCF7	IC₅₀	>500 μM Compound: 9	Antiproliferative activity in human MCF7 cells by sulforhodamine B assay Antiproliferative activity in human MCF7 cells by sulforhodamine B assay	[PMID: 29120172]
MCF7	IC₅₀	10.37 μM Compound: 2	Cytotoxicity against human MCF7 cells after 96 hrs by SRB colorimetric assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB colorimetric assay	[PMID: 20472329]
MCF7	IC₅₀	10.42 μM Compound: 2	Cytotoxicity against human MCF7 cells assessed as cell viability after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as cell viability after 96 hrs by SRB assay	[PMID: 23973824]
MCF7	IC₅₀	18.2 μM Compound: 1, BetA, Betulonic acid	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 25874331]
MCF7	IC₅₀	19.32 μg/mL Compound: Betunolic acid	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 21106454]
MCF7	IC₅₀	29 μM Compound: 7, betulonic acid	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 15270560]
MCF7	IC₅₀	49 μM Compound: 17	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 17346076]
MDA-MB-231	CC₅₀	60.9 μM Compound: 9	Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay	[PMID: 29120172]
MDA-MB-231	IC₅₀	>20 μg/mL Compound: Betunolic acid	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 21106454]
MDA-MB-231	IC₅₀	>500 μM Compound: 9	Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay	[PMID: 29120172]
MDA-MB-231	IC₅₀	9.77 μM Compound: 6	Antiproliferative activity against human MDA-MB-231 cells after 3 days by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 3 days by MTT assay	[PMID: 19691293]
MGC-803	IC₅₀	17.7 μM Compound: 1, BetA, Betulonic acid	Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay	[PMID: 25874331]
MIA PaCa-2	IC₅₀	>10 μM Compound: 7	Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability after 48 hrs by SRB assay Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 28500966]
MOLT-4	ED₅₀	1.2 μg/mL Compound: 13	Cytotoxic activity against human MOLT-4 cell line was measured after 72 hr using MTT assay Cytotoxic activity against human MOLT-4 cell line was measured after 72 hr using MTT assay	[PMID: 15225732]
MRC5	IC₅₀	29.5 μM Compound: 5a	Cytotoxicity against human MRC5 cells incubated for 72 hrs by MTS assay Cytotoxicity against human MRC5 cells incubated for 72 hrs by MTS assay	[PMID: 31677446]
MRC5	IC₅₀	30 μM Compound: 1a	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 36174412]
Neutrophil	IC₅₀	127.64 μg/mL Compound: Betunolic acid	Antiinflammatory activity in human Neutrophil assessed as inhibition of elastase release at 10 ug/ml Antiinflammatory activity in human Neutrophil assessed as inhibition of elastase release at 10 ug/ml	[PMID: 21106454]
Neutrophil	IC₅₀	16.77 μg/mL Compound: Betunolic acid	Antiinflammatory activity in human Neutrophil assessed as inhibition of superoxide anion release at 10 ug/ml Antiinflammatory activity in human Neutrophil assessed as inhibition of superoxide anion release at 10 ug/ml	[PMID: 21106454]
NIH3T3	EC₅₀	13.1 μM Compound: 4	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 26547057]
NIH3T3	EC₅₀	19.4 μM Compound: 2	Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32956968]
PA-1	ED₅₀	1.2 μg/mL Compound: 13	Cytotoxic activity against human PA-1 cell line was measured after 72 hr using MTT assay Cytotoxic activity against human PA-1 cell line was measured after 72 hr using MTT assay	[PMID: 15225732]
PC-3	IC₅₀	>10 μM Compound: 7	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by SRB assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 28500966]
PC-3	IC₅₀	13.9 μM Compound: 1, BetA, Betulonic acid	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 25874331]
PC-3	IC₅₀	15 μM Compound: 1b	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 17371067]
PC-3	IC₅₀	15 μM Compound: 7, betulonic acid	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 15270560]
Platelet	IC₅₀	>50 μg/mL Compound: Betunolic acid	Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation by aggregometry Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation by aggregometry	[PMID: 21106454]
Platelet	IC₅₀	44.71 μg/mL Compound: Betunolic acid	Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by aggregometry Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by aggregometry	[PMID: 21106454]
SiHa	CC₅₀	116.8 μM Compound: 9	Cytotoxic activity in human SiHa cells by sulforhodamine B assay Cytotoxic activity in human SiHa cells by sulforhodamine B assay	[PMID: 29120172]
SiHa	IC₅₀	>500 μM Compound: 9	Antiproliferative activity in human SiHa cells by sulforhodamine B assay Antiproliferative activity in human SiHa cells by sulforhodamine B assay	[PMID: 29120172]
SK-MEL-2	ED₅₀	0.9 μg/mL Compound: 3	Cytotoxicity against cultured human melanoma (MEL-2) cell line. Cytotoxicity against cultured human melanoma (MEL-2) cell line.	[PMID: 9873420]
SK-MEL-2	IC₅₀	26 μM Compound: 1b	Cytotoxicity against human SK-MEL-2 cells after 72 hrs by MTT assay Cytotoxicity against human SK-MEL-2 cells after 72 hrs by MTT assay	[PMID: 17371067]
SK-MEL-2	IC₅₀	26 μM Compound: 7, betulonic acid	Cytotoxicity against human SK-MEL-2 cells after 72 hrs by MTT assay Cytotoxicity against human SK-MEL-2 cells after 72 hrs by MTT assay	[PMID: 15270560]
SW-1736	IC₅₀	3.05 μM Compound: 2	Cytotoxicity against human SW1736 cells after 96 hrs by SRB colorimetric assay Cytotoxicity against human SW1736 cells after 96 hrs by SRB colorimetric assay	[PMID: 20472329]
SW948	IC₅₀	19.17 μM Compound: 6	Antiproliferative activity against human SW948 cells after 3 days by XTT assay Antiproliferative activity against human SW948 cells after 3 days by XTT assay	[PMID: 19691293]
U2OS	IC₅₀	38 μM Compound: 5a	Cytotoxicity against human U2OS cells incubated for 72 hrs by MTS assay Cytotoxicity against human U2OS cells incubated for 72 hrs by MTS assay	[PMID: 31677446]
U2OS	IC₅₀	38 μM Compound: 1a	Cytotoxicity against human U2OS cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human U2OS cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 36174412]
U-87MG ATCC	IC₅₀	159 μM Compound: 1b	Cytotoxicity against human U87-Mg cells after 72 hrs by MTT assay Cytotoxicity against human U87-Mg cells after 72 hrs by MTT assay	[PMID: 17371067]
U-937	ED₅₀	2.8 μg/mL Compound: 13	Cytotoxic activity against human U937 cell line was measured after 72 hr using MTT assay Cytotoxic activity against human U937 cell line was measured after 72 hr using MTT assay	[PMID: 15225732]
Vero	CC₅₀	>400 μM Compound: 4b	Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay	[PMID: 29326018]
Vero	CC₅₀	>500 μM Compound: 9	Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay	[PMID: 29120172]
Vero	CC₅₀	112 μM Compound: 14	Cytotoxicity against Vero E6 cells by MTT assay Cytotoxicity against Vero E6 cells by MTT assay	[PMID: 17663539]
Vero	CC₅₀	35.6 μM Compound: Betulonic acid	Cytotoxicity against African green monkey Vero cells assessed as cell viability after 2 days by trypan blue exclusion assay Cytotoxicity against African green monkey Vero cells assessed as cell viability after 2 days by trypan blue exclusion assay	[PMID: 26112446]
Vero	EC₅₀	0.63 μM Compound: 14	Antiviral activity against SARS coronavirus in Vero E6 cells assessed as inhibition of viral replication by ELISA Antiviral activity against SARS coronavirus in Vero E6 cells assessed as inhibition of viral replication by ELISA	[PMID: 17663539]
Vero	IC₅₀	>500 μM Compound: 9	Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay	[PMID: 29120172]

In Vitro

Betulonic acid (72 h) inhibits the growth of various types of human tumor cell lines, including MGC-803, PC3, Bcap-37, A375, MCF-7 tumor cell lines, with IC₅₀s of 17.7, 13.9, 25.7, 28.9, 18.2 μM, respectively^[2].
Betulonic acid has antiplasmodial activity, with IC₅₀ of 10 μM^[3].
Betulonic acid inhibits HSV-1, ECHO6 and influenza FPV viruses, with EC₅₀s of 0.9, 73.32, and 5.7 μM, respectively^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

Chemical Information

CAS. Nr. 4481-62-3
Appearance Solid
Molecular Weight 454.68
Formel C₃₀H₄₆O₃
Color White to off-white
SMILES

CC1(C)C(CC[C@]2(C)[C@@]3([H])CC[C@]4([H])[C@@]5([H])[C@H](C(C)=C)CC[C@@](C(O)=O)5CC[C@](C)4[C@@](C)3CC[C@@]12[H])=O
Synonyms

Betunolic acid; Liquidambaric acid; (+)-Betulonic acid
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
- Plants
- Other Families Extract
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (5)

All

Sort by:

Journal Impact Factor

Pharmacol Res

Time-dependent proteomics and drug response in expanding cancer cells. [Abstract]

2024 Jun:204:107208. PMID: 38729587
Life Sci

TRAF2 mediates Wnt-induced β-catenin nuclear translocation by associating with the nuclear pore complex. [Abstract]

2025 Sep 15:377:123722. PMID: 40393561
Catal Today

2020 Aug.
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
Res Sq

2025 May 21.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 5 mg/mL (11.00 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1993 mL

10.9967 mL

21.9935 mL

5 mM

0.4399 mL

2.1993 mL

4.3987 mL

10 mM

0.2199 mL

1.0997 mL

2.1993 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 0.67 mg/mL (1.47 mM); Clear solution

This protocol yields a clear solution of ≥ 0.67 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (6.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 0.67 mg/mL (1.47 mM); Clear solution

This protocol yields a clear solution of ≥ 0.67 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (6.7 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

All Signal Pathway Related

Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Bastos DZL, et, al. Biotransformation of betulinic and betulonic acids by fungi. Phytochemistry. 2007 Mar;68(6):834-9. [Content Brief]

[2]. Yang SJ, et, al. Synthesis and biological evaluation of betulonic acid derivatives as antitumor agents. Eur J Med Chem. 2015;96:58-65. [Content Brief]

[3]. Sá MS, et, al. Antimalarial activity of betulinic acid and derivatives in vitro against Plasmodium falciparum and in vivo in P. berghei-infected mice. Parasitol Res. 2009 Jul;105(1):275-9. [Content Brief]

[4]. Pavlova NI, et, al. Antiviral activity of betulin, betulinic and betulonic acids against some enveloped and non-enveloped viruses. Fitoterapia. 2003 Jul;74(5):489-92. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1993 mL	10.9967 mL	21.9935 mL	54.9837 mL
	5 mM	0.4399 mL	2.1993 mL	4.3987 mL	10.9967 mL
	10 mM	0.2199 mL	1.0997 mL	2.1993 mL	5.4984 mL

Bioz

Keywords

Betulonic acid

5 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Betulonic acid

Publications Citing Use of MedChemExpress (MCE) Betulonic acid

Alle Parasite Isoform-spezifische Produkte anzeigen

Alle HSV Isoform-spezifische Produkte anzeigen